Biography
I am Dr. Osama Ashry Ahmed Gheith, who graduated in 1987 from Mansoura faculty of medicine, Egypt. I have held an MD degree in Internal Medicine and Nephrology since 2003. I have been trained at Mansoura urology and nephrology center, Mansoura University, Egypt from 1991 till 2008 when I join the work at Hamed Al-Essa organ transplant center.
I am a member of the following societies: International Society of Nephrology (ISN), European Dialysis Transplantation Association (EDTA), African Association of Nephrology (AFRAN), Arab Society of Nephrology, and Egyptian Society of Nephrology (ESN).
I have long experience with all nephrology activities including all dialysis modalities, medical care of more than 3500 renal transplant recipients, and surgical Skills of importance in the field of nephrology as vascular access creation, PD catheter insertion, and renal biopsies. Moreover, I am interested in training and supervising Junior Staff in nephrology and renal transplant (in Egypt, Yemen, and Kuwait).
I have completed the NIH Web-based training course “Protecting Human Research Participants”. I am interested in research work and have over 12 research projects ongoing in the department. I am an author and/or co-author of over 85 publications in peer-reviewed international journals. In addition to several abstracts in many Middle East and international conferences. I am interested in the field of immunosuppression in renal transplantation, post-transplant diabetes, infection, and anemia.
I won some of the research prizes with the special concern of Emirates medical association –Nephrology Society EMAN YOUNG INVESTIGATOR AWARD –during the 12th congress of the Arab society of nephrology and renal transplantation 2014, 6th ISN EMAN Update Course in Nephrology 2014, 10-13December 2014 Dubai, UAE; one of the top 5 posters presented in ESNT 2018 (impact of HLA DR mismatch in elderly renal transplant recipients regardless donor sources: single-center experience from the middle east) and one of the top 5 posters presented in ESNT 2019 (Screening for BK viremia/viruria and the Impact of Management of BK Virus Nephropathy in Renal Transplant Recipients).
Covid-19 positive kidney transplant recipients behave differently compared to non-transplant patients ICU: single center experience
Osama Gheith1,2, Ayman M. Nagib1,2, Nabil Alserwy1, Mohamed Emam1, Mohamed M. Abuelmagd1, Mohamed Adel1, Ahmed K. Al-Qallaf3, Mohamed Shaker1, Ahmad M. Abbas1,4, Medhat A. Halim1, Tarek Said1, Prasad Nair1, Mahmoud M. khaled1, Mahmoud M. khaled1, Mohamed A. Hammad1, Zohair A. Fayyad1, Ahmed F. Atta1, Ahmed Y. Mostafa1, Ahmed S. Deraz1, Zakaria E. Zakaria1, Khaled A. Atea1, Hasaneen H. Aboatya1, Mohamed E. Ameenn1, Mohamed A. Moneim1, Amro M. Mahmoud 3, Torki M. AlOtaibi1.
1Nephrology , OTC kuwait, Kuwait, Kuwait; 2Nephrology , MUNC, Mansoura, Egypt; 3Nephrology , Jaber hospital, Kuwait, Kuwait; 4chest , Faculty of medicine, Zagazig, Egypt
Introduction: COVID-19 is an ongoing pandemic that has altered our lives especially that of kidney transplant recipients (KTR).
Aim: We aimed to compare COVID-19 positive kidney transplant recipients with non-transplant positive cases that were managed in the intensive care unit (ICU) during the pandemic.
Methods: Out of 2000 KTR that was followed up in Hamed Al-Essa Organ transplant center in Kuwait, we collected data of all COVID-19-positive KTR (group 1, n=79) till the end of January 2021. Clinical features, management details, and both patient and renal outcomes were reported and compared with (group 2, n=445) non-transplant cases admitted during the same period in the ICU of a single isolation hospital in Kuwait during the pandemic.
Results: Most of the cases were males (74% vs.73%), aged 51.7±16 and 60.8± 14 years in the 2 groups respectively. Both groups were comparable regarding patients with diabetes mellitus (50.6 vs. 55.2%), hypertension (62% vs 57.1%), ischemic heart disease (20% vs 19.8%) and chronic kidney disease (1.3% vs 1.6%). Fever, cough, body aches, and gastrointestinal symptoms were the most frequent presentation among KTR. Meanwhile, complicated cases with sepsis, volume depletion, shock, and ARDS predominated among the non-transplant group (p<0.05). Therapeutic management included anticoagulation (81 %) in both groups, while steroid and tocilizumab were used frequently among the non-transplant group (8.7%).
Within 30 days follow up, the non-transplant group showed a significantly higher number of cases with acute kidney injury ( 47.8% vs. 26.7%), respiratory failure requiring mechanical ventilation, and mortality rate (54.4%. vs. 22.8%).
Conclusion: we reported a better outcome of ICU admitted COVID-19 positive KTR in comparison with the non-transplant patients possibly due to younger age modified immunosuppression.
right-click to download
